[시장보고서]세계의 슈퍼 제네릭 의약품 시장 : 산업 동향 및 세계 전망(-2035년) : 치료 영역별, 투여 경로별, 분자 유형별, 저분자 유형별, 제품 유형별, 주요 지역별 분석

세계의 슈퍼 제네릭 의약품 시장 : 산업 동향 및 세계 전망(-2035년) : 치료 영역별, 투여 경로별, 분자 유형별, 저분자 유형별, 제품 유형별, 주요 지역별 분석

Super Generics Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Therapeutic Area, Route of Administration, Type of Molecule, Type of Small Molecule, Type of Product and Key Geographical Regions

상품코드 : 1490320

리서치사 : Roots Analysis

발행일 : 2024년 03월

페이지 정보 : 영문 257 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,799

￦ 6,873,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999

￦ 10,023,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599

￦ 15,179,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999

￦ 25,778,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

슈퍼 제네릭 의약품 시장은 2024년 840억 달러 규모에 이르고, 2024-2035년의 예측 기간 동안 8%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.

제약 분야에서 슈퍼 제네릭 의약품은 특허 독점권을 잃은 오리지널 의약품의 개량형 의약품을 의미합니다. 이러한 정교한 약리학 적 개입은 종종 복합 제네릭 또는 부가가치 제네릭 의약품이라고 불리며 브랜드 의약품을 대체하는 제네릭 의약품으로 작용합니다. 주목할 만한 것은 2022년 미국 FDA가 32,000개 이상의 제네릭 의약품을 승인했으며, 미국 처방전의 91%가 제네릭 의약품으로 채워질 것이라는 점입니다. 이러한 개량형 슈퍼제네릭은 약물 전달, 제조 공정 및 재제형 기술의 발전 가능성을 내포하고 있습니다. 이 부가가치 부문은 지속적인 기술 혁신의 틀 안에서 운영되고 있으며, 제약 시장에 유망한 기회를 제공합니다. 슈퍼 제네릭 의약품은 일반적으로 3-7년간 독점 판매권을 부여받아 개발사가 기존 제네릭 의약품에 비해 상대적으로 높은 수익률을 달성할 수 있으며, FDA(미국), EMA(유럽) 등 규제 기관은 이러한 의약품을 면밀히 검토하여 슈퍼 제네릭 의약품 시장 진입을 승인합니다. 슈퍼 제네릭 의약품 시장 진입을 승인합니다.

슈퍼 제네릭 의약품의 개발은 안전성, 유효성 및 품질을 보장하기 위해 엄격한 연구 개발이 필요합니다. 업계 이해관계자들은 표준 오리지널 의약품과의 생물학적 동등성 및 치료적 동등성을 입증하기 위해 대규모 전임상 및 임상시험에 투자하고 있습니다. 전 세계 규제 당국이 더 많은 제네릭 의약품을 승인함에 따라 업계 경쟁은 더욱 치열해질 것으로 예상됩니다. 이러한 경쟁 심화의 주요 결과는 제네릭 의약품의 비용 감소와 개발사의 이익률 하락으로 이어질 것입니다. 따라서 특허가 만료된 의약품 시장의 성장을 유지하기 위해 기업들은 점차 혁신적인 의약품 변형 기술을 채택하여 더 높은 상업적 전망을 가진 고부가가치 의약품을 생산하고 있습니다. 소매 약국과 온라인 약국은 다양한 제네릭 의약품을 제공하여 소비자의 의료 비용을 절감하고 있습니다. 또한 유럽의 많은 국가에서 약사는 의료 서비스 제공업체가 특별히 지정하지 않는 한 브랜드 처방전을 제네릭 의약품으로 대체할 수 있는 권한을 가지고 있습니다.

이 보고서는 세계의 슈퍼 제네릭 의약품 시장에 대해 조사했으며, 시장 개요와 함께 치료 영역별/투여 경로별/분자 유형별/저분자 유형별/제품 유형별/주요 지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.

본 장의 개요
주요 전제와 조사 방법
슈퍼 제네릭 의약품 시장 전체, 과거 동향(2018년-2022년) 및 예측 추정(2023년-2035년)
슈퍼 제네릭 의약품 시장 : 치료 영역별, 2023년-2035년
슈퍼 제네릭 의약품 시장 : 투여 경로별, 2023년-2035년
슈퍼 제네릭 의약품 시장 : 분자 유형별, 2023년-2035년
슈퍼 제네릭 의약품 시장 : 저분자 유형별, 2023년-2035년
슈퍼 제네릭 의약품 시장 : 제품 유형별, 2023년-2035년
슈퍼 제네릭 의약품 시장 : 지역별, 2023년-2035년

제14장 결론

제15장 부록 1 : 표 형식 데이터

제16장 부록 II : 기업 및 단체 리스트

LSH

영문 목차

영문목차

Super Generics Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Therapeutic Area (Cardiovascular Disorders, Metabolic Disorders, Neurological Disorders, Oncological Disorders, Respiratory Disorders and Other Disorders), Route of Administration (Intravenous, Oral, Subcutaneous and Others), Type of Molecule (Small and Other Molecules), Type of Small Molecule (Generics and Other Small Molecules), Type of Product (Aerosols, Capsules, Prefilled Syringes, Tablets, Vials and Other Products) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World)

The Super Generics Market is valued at USD 84 billion in 2024 growing at a CAGR of 8% during the forecast period 2024-2035.

In the pharmaceutical domain the super generic drugs represent the enhanced versions of original pharmaceuticals that have lost their patent exclusivity. These refined pharmacological interventions are often termed as complex generics or value-added generics and serve as generic alternatives to their branded counterparts. Notably, in 2022, the US FDA sanctioned over 32,000 generic drug products, with 91% of all US prescriptions being filled with generics. These improved super generics hold the potential for advancements in drug delivery, manufacturing processes, and reformulation techniques. This value-added segment operates within a framework of ongoing innovation, offering promising opportunities in the pharmaceutical market. Super generic drugs are granted a form of marketing exclusivity, typically for 3 to 7 years, allowing developers to achieve relatively high profit margins as compared to the conventional generics. Regulatory bodies such as the FDA (in the US) or the EMA (in Europe) scrutinize these drugs and grant approval for their entry in the super generics market.

Developing super generic drugs entails rigorous research and development to ensure their safety, efficacy, and quality. Industry stakeholders invest in extensive preclinical and clinical studies to establish bioequivalence or therapeutic equivalence with the reference brand-name drug. As regulatory agencies worldwide greenlight more generic drugs, competition in the industry is expected to intensify. The primary consequence of this heightened competition is a decrease in the cost of generics, leading to reduced profit margins for developers. Hence, to sustain growth in the off-patent drug market, companies are progressively adopting innovative drug alteration techniques to create value-added medicinal products with better commercial prospects. Retail and online pharmacies offer a wide array of generic options, empowering consumers to lower healthcare expenses. Moreover, in numerous European countries, pharmacists have the authority to substitute brand-name prescriptions with generic equivalents unless otherwise specified by healthcare. providers.

Key Market Segments

Therapeutic Area

Cardiovascular Disorders
Metabolic Disorders
Neurological Disorders
Oncological Disorders
Respiratory Disorders
Other Disorders

Route of Administration

Intravenous
Oral
Subcutaneous
Others

Type of Molecule

Small
Other Molecules

Type of Small Molecule

Generics
Other Small Molecule

Type of Product

Aerosols
Capsules
Prefilled Syringes
Tablets
Vials
Other Products

Geography

North America
Europe
Asia-Pacific
Rest of the World

Research Coverage:

A summary of super generics technologies, including details on various pertinent parameters such as the type of drug modification, technology type, molecules formulated/delivered, route of administration, and type of value addition. This encompasses information on technology providers offering platforms/solutions for super generic drug development, including their year of establishment, company size (in terms of the number of employees), and headquarters location.
An insightful analysis of the competitiveness of the technologies compiled in our database, considering pertinent parameters including supplier power (based on the company size of technology providers) and technology competitiveness, such as the type of molecule, impact on drug properties, and route of administration.
Detailed profiles of prominent technology developers involved in this domain are provided, offering an overview of the company, its financial information where available, technology portfolio, recent advancements, and future outlook.
A compilation of marketed generics that, in our assessment, are poised to be developed as super generics in the near future, derived from a thorough analysis considering various pertinent parameters. These parameters include the current annual cost of treatment of the parent drug, year of patent expiry, sales revenues generated in the year prior to patent expiry, target therapeutic area, and the number of competitor (generic) drugs available in the market.
Comprehensive case studies are presented for five approved supergeneric drugs, encompassing an overview of the drug along with details on the original/parent drug, the value proposition offered by the supergeneric version, pricing strategies adopted by the developer where available, annual sales revenues of the supergeneric and parent drug if available, and key learnings/takeaways from each case study.
A discourse on associated trends, key drivers, and challenges within a SWOT framework, which are anticipated to influence the evolution of the industry, accompanied by a Harvey ball analysis to illustrate the relative impact of each SWOT parameter on the overall super generics market.
A thorough assessment of the current market size, existing opportunity, and the future growth potential of the super generics market over the next decade is conducted. Drawing from various parameters, including likely adoption trends, we have formulated an informed estimate on the market evolution during the forecast period from 2024 to 2035. The report also includes an analysis of the likely distribution of current and forecasted opportunities within the super generics market. Additionally, to accommodate future uncertainties and enhance the robustness of our model, three forecast scenarios-conservative, base, and optimistic-are provided, representing different trajectories of growth in the super generics market.

Key Benefits of Buying this Report

The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
The report provides stakeholders with a pulse on the Super Generics Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

Accord Healthcare
Alcon Laboratories
Ascendia Pharmaceuticals
Azurity Pharmaceuticals
Baxter
CritiTech
Crossject
DelSiTech
Dr. Reddy's Laboratories
Exela Pharma Sciences
Harrow Health
Heron Therapeutics
Hikma Pharmaceuticals
Intellipharmaceutics International
Kashiv BioSciences
Latitude Pharmaceuticals
Mayne Pharma
meda pharmaceuticals
Neurelis
Rubicon Research
Sun Pharmaceutical industries
Taiwan Liposome Company
Tesa Labtec
Teva Pharmaceutical

Table Of Contents

1. PREFACE

1.1 Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
- 2.7.1. Demographics
- 2.7.2. Economic Factors
- 2.7.3. Government Regulations
- 2.7.4. Supply Chain
- 2.7.5. COVID Impact / Related Factors
- 2.7.6. Market Access
- 2.7.7. Healthcare Policies
- 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3.1. Chapter Overview
3.2. Market Dynamics
- 3.2.1. Time Period
  - 3.2.1.1. Historical Trends
  - 3.2.1.2. Current and Forecasted Estimates
- 3.2.2. Currency Coverage
  - 3.2.2.1. Overview of Major Currencies Affecting the Market
  - 3.2.2.2. Impact of Currency Fluctuations on the Industry
- 3.2.3. Foreign Exchange Impact
  - 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
  - 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 3.2.4. Recession
  - 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
  - 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
- 3.2.5. Inflation
  - 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

5.1. Chapter Overview
5.2. Overview of Generic Drugs
- 5.2.1. Key Challenges within the Generics Industry
  - 5.2.1.1. Policy Changes
  - 5.2.1.2. Increasing Competition
  - 5.2.1.3. Price Erosion
5.3. Super Generics
- 5.3.1. Techniques Used for the Development of Super Generics
- 5.3.2. Regulatory Pathways for Approval of Super Generics
5.4. Advantages of Super Generics
- 5.4.1. Improved Efficacy
- 5.4.2. Increased IP Protection
- 5.4.3. Cost and Time Efficient Development Process
5.5. Challenges Related to Super Generics
5.6. Future Perspectives

6. SUPER GENERIC DRUGS: MARKET LANDSCAPE

6.1. Chapter Overview
6.2. Super Generic Drugs: Overall Market Landscape
- 6.2.1. Analysis by Route of Administration
- 6.2.2. Analysis by Target Indication
- 6.2.3. Analysis by Target Therapeutic Area
- 6.2.4. Analysis by Submission Classification Code
- 6.2.5. Most Active Players: Analysis by Number of Super Generic Drugs

7. SUPER GENERIC TECHNOLOGIES: MARKET LANDSCAPE

7.1 Chapter Overview
7.2. Super Generic Technologies: Overall Market Landscape
- 7.2.1 Analysis by Type of Drug Modification
- 7.2.2 Analysis by Type of Technology
- 7.2.3 Analysis by Type of Molecules Formulated / Delivered
- 7.2.4 Analysis by Route of Administration
- 7.2.5 Analysis by Type of Value Addition
7.3. Super Generics Technology Developers
- 7.3.1 Analysis by Year of Establishment
- 7.3.2 Analysis by Company Size
- 7.3.3 Analysis by Location of Headquarters (Region)
- 7.3.4. Most Active Players: Analysis by Number of Super Generics Technologies

8. TECHNOLOGY COMPETITIVENESS ANALYSIS

8.1. Chapter Overview
8.2. Methodology and Key Parameters
8.3. Technologies Offered by Companies based in North America
- 8.3.1 Technologies Offered by Companies based in North America (Peer Group I)
- 8.3.2 Technologies Offered by Companies based in North America (Peer Group II)
8.4 Technologies Offered by Companies based in Europe
8.5. Technologies Offered by Companies based in Asia-Pacific

9. COMPANY PROFILES

9.1. Chapter Overview
9.2. Ascendia Pharmaceuticals
- 9.2.1. Company Overview
- 9.2.2. Technology Portfolio
  - 9.2.2.1. NanoSol
  - 9.2.2.2. AmorSol
  - 9.2.2.3. EmulSol
- 9.2.3. Recent Developments and Future Outlook
9.3. CritiTech
- 9.3.1. Company Overview
- 9.3.2. Technology Portfolio
  - 9.3.2.1. Spray Drying Technology
  - 9.3.2.2. Supercritical Precipitation Technology
- 9.3.3. Recent Developments and Future Outlook
9.4. Crossject
- 9.4.1. Company Overview
- 9.4.2. Technology Portfolio
  - 9.4.2.1. ZENEO(R)
- 9.4.3. Recent Developments and Future Outlook
9.5. DelSiTech
- 9.5.1. Company Overview
- 9.5.2. Technology Portfolio
  - 9.5.2.1. DelSiTech(TM) Silica
- 9.5.3. Recent Developments and Future Outlook
9.6. Heron Therapeutics
- 9.6.1. Company Overview
- 9.6.2. Technology Portfolio
  - 9.6.2.1. Biochronomer(R)
- 9.6.3. Recent Developments and Future Outlook
9.7. Latitude Pharmaceuticals
- 9.7.1. Company Overview
- 9.7.2. Technology Portfolio
  - 9.7.2.1. Nano-E(TM)
  - 9.7.2.2. PG-Depot(TM)
  - 9.7.2.3. ARTSS(TM)
  - 9.7.2.4. RFAP(TM) Matrix
  - 9.7.2.5. RTTS
  - 9.7.2.6. 24H(TM)
  - 9.7.2.7. MiniSpheres
  - 9.7.2.8. GelPatch
- 9.7.3. Recent Developments and Future Outlook
9.8. Mayne Pharma
- 9.8.1. Company Overview
- 9.8.2. Financial Information
- 9.8.3. Technology Portfolio
  - 9.8.3.1. SUBA(TM)
  - 9.8.3.2. Cleantaste(TM)
  - 9.8.3.3. Pellet Technology
- 9.8.4. Recent Developments and Future Outlooks
9.9. Neurelis
- 9.9.1. Company Overview
- 9.9.2. Technology Portfolio
  - 9.9.2.1. Intravail(R)
  - 9.9.2.2. ProTek(R)
  - 9.9.2.3. Hydrogel(TM)
- 9.9.3. Recent Developments and Future Outlook
9.10. Rubicon Research
- 9.10.1. Company Overview
- 9.10.2. Technology Portfolio
  - 9.10.2.1. RubiERT(R)
  - 9.10.2.2. RubiDT(R)
  - 9.10.2.3. RubiReten(R)
  - 9.10.2.4. RubiSRL(R)
9.11. Taiwan Liposome Company
- 9.11.1. Company Overview
- 9.11.2. Financial Information
- 9.11.3. Technology Portfolio
  - 9.11.3.1. BioSeizer(R)
  - 9.11.3.2. NanoX(TM)
  - 9.11.3.3. Polymeric Micelle
- 9.11.4. Recent Developments and Future Outlook
9.12. tesa Labtec
- 9.12.1. Company Overview
- 9.12.2. Technology Portfolio
  - 9.12.2.1. Transfilm(R)
  - 9.12.2.2. Mucofilm(R)
  - 9.12.2.3. Rapidfilm(R)
- 9.12.3. Recent Developments and Future Outlook

10 CASE STUDY: APPROVED SUPER GENERIC DRUGS

10.1. Chapter Overview
10.2. Austedo(R)
- 10.2.1. Overview
- 10.2.2. Originator Drug Overview
- 10.2.3. Value Proposition
- 10.2.4. Financial Information
- 10.2.5. Key Learnings
10.3. Abraxane(R)
- 10.3.1. Overview
- 10.3.2. Originator Drug Overview
- 10.3.3. Value Proposition
- 10.3.4. Financial Information
- 10.3.5. Key Learnings
10.4. Avycaz(R)
- 10.4.1. Overview
- 10.4.2. Originator Drug Overview
- 10.4.3. Value Proposition
- 10.4.4. Financial Information
- 10.4.5. Key Learnings
10.5. Procysbi(R)
- 10.5.1. Overview
- 10.5.2. Originator Drug Overview
- 10.5.3. Value Proposition
- 10.5.4. Financial Information
- 10.5.5. Key Learnings
10.6. Trokendi XR(R)
- 10.6.1. Overview
- 10.6.2. Originator Drug Overview
- 10.6.3. Value Proposition
- 10.6.4. Financial Information
- 10.6.5. Key Learnings

11. SUPER GENERICS: LIKELY DRUG CANDIDATES

11.1. Chapter Overview
11.2. Marketed Drug Candidates
- 11.2.1. Most Likely Drug Candidates for Super Generics
- 11.2.2. Likely Drug Candidates for Super Generics
- 11.2.3. Less Likely Drug Candidates for Super Generics
- 11.2.4. Least Likely Drug Candidates for Super Generics

12. SWOT ANALYSIS

12.1. Chapter Overview
12.2. Strengths
12.3. Weakness
12.4. Opportunities
12.5. Threats
12.6. Concluding Remarks

13. GLOBAL SUPER GENERICS MARKET

13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Overall Super Generics Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.4. Super Generics Market: Distribution by Therapeutic Area, 2023-2035
13.5. Super Generics Market: Distribution by Route of Administration, 2023-2035
13.6. Super Generics Market: Distribution by Type of Molecule, 2023-2035
13.7. Super Generics Market: Distribution by Type of Small Molecule, 2023-2035
13.8. Super Generics Market: Distribution by Type of Product, 2023-2035
13.9. Super Generics Market: Distribution by Geography, 2023-2035
- 13.9.1. Super Generics Market in North America, 2023-2035
  - 13.9.1.1. Super Generics Market in North America: Distribution by Therapeutic Area, 2023-2035
    - 13.9.1.1.1. Super Generics Market for Oncological Disorders in North America, 2023-2035
    - 13.9.1.1.2. Super Generics Market for Metabolic Disorders in North America, 2023-2035
    - 13.9.1.1.3. Super Generics Market for Neurological Disorders in North America, 2023-2035
    - 13.9.1.1.4. Super Generics Market for Respiratory Disorders in North America, 2023-2035
    - 13.9.1.1.5. Super Generics Market for Cardiovascular Disorders in North America, 2023-2035
    - 13.9.1.1.6. Super Generics Market for Other Disorders in North America, 2023-2035
  - 13.9.1.2. Super Generics Market: Distribution by Route of Administration in North America
    - 13.9.1.2.1. Super Generics Market for Oral Route of Administration in North America, 2023-2035
  - 13.9.12.2. Super Generics Market for Subcutaneous Route of Administration in North America, 2023-2035
    - 13.9.1.2.3. Super Generics Market for Intravenous Route of Administration in North America, 2023-2035
    - 13.9.1.2.4. Super Generics Market for Other Routes of Administration in North America, 2023-2035
  - 13.9.1.3. Super Generics Market: Distribution by Type of Molecule in North America
    - 13.9.1.3.1. Super Generics Market for Small Molecule in North America, 2023-2035
    - 13.9.1.3.2. Super Generics Market for Biologics in North America, 2023-2035
  - 13.9.1.4. Super Generics Market: Distribution by Type of Small Molecules in North America
    - 13.9.1.4.1 Super Generics Market for Complex Generics in North America, 2023-2035
    - 13.9.1.4.2. Super Generics Market for Other Small Molecules in North America, 2023-2035
  - 13.9.1.5. Super Generics Market: Distribution by Type of Product Offered in North America
    - 13.9.1.5.1. Super Generics Market for Prefilled Syringe in North America, 2023-2035
    - 13.9.1.5.2. Super Generics Market for Vials in North America, 2023-2035
    - 13.9.1.5.3. Super Generics Market for Aerosols in North America, 2023-2035
    - 13.9.1.5.4. Super Generics Market for Tablets in North America, 2023-2035
    - 13.9.1.5.5. Super Generics Market for Capsules in North America, 2023-2035
    - 13.9.1.5.6. Super Generics Market for Other Types of Products in North America, 2023-2035
- 13.9.2. Super Generics Market in Europe, 2023-2035
  - 13.9.2.1. Super Generics Market in Europe: Distribution by Therapeutic Area, 2023-2035
    - 13.9.2.1.1. Super Generics Market for Oncological Disorders in Europe, 2023-2035
    - 13.9.2.1.2. Super Generics Market for Metabolic Disorders in Europe, 2023-2035
    - 13.9.2.1.3. Super Generics Market for Neurological Disorders in Europe, 2023-2035
    - 13.9.2.1.4. Super Generics Market for Respiratory Disorders in Europe, 2023-2035
    - 13.9.2.1.5. Super Generics Market for Cardiovascular Disorders in Europe, 2023-2035
    - 13.9.2.1.6. Super Generics Market for Other Disorders in Europe, 2023-2035
  - 13.9.2.2. Super Generics Market Distribution by Route of Administration in Europe
    - 13.9.2.2.1. Super Generics Market for Oral Route of Administration in Europe, 2023-2035
    - 13.9.2.2.2. Super Generics Market for Subcutaneous Route of Administration in Europe, 2023-2035
    - 13.9.2.2.3. Super Generics Market for Intravenous Route of Administration in Europe, 2023-2035
    - 13.9.2.2.4. Super Generics Market for Other Routes of Administration in Europe, 2023-2035
  - 13.9.2.3. Super Generic Drugs Market: Distribution by Type of Molecule in Europe
    - 13.9.2.3.1. Super Generic Drugs Market for Small Molecule in Europe, 2023-2035
    - 13.9.2.3.2. Super Generic Drugs Market for Biologics in Europe, 2023-2035
  - 13.9.2.4. Super Generic Drugs Market: Distribution by Type of Small Molecules in Europe
    - 13.9.2.4.1 Super Generic Drugs Market for Complex Generics in Europe, 2023-2035
    - 13.9.2.4.2. Super Generics Market for Other Small Molecules in Europe, 2023-2035
  - 13.9.2.5. Super Generic Market: Distribution by Type of Product Offered in Europe
    - 13.9.2.5.1. Super Generic Market for Prefilled Syringe in Europe, 2023-2035
    - 13.9.2.5.2. Super Generic Market for Vials in Europe, 2023-2035
    - 13.9.2.5.3. Super Generic Market for Aerosols in Europe, 2023-2035
    - 13.9.2.5.4. Super Generic Market for Tablets in Europe, 2023-2035
    - 13.9.2.5.5. Super Generic Market for Capsules in Europe, 2023-2035
    - 13.9.2.5.6. Super Generics Market for Other Types of Products in Europe, 2023-2035
- 13.9.3. Super Generics Market in Asia-Pacific, 2023-2035
  - 13.9.3.1. Super Generics Market in Asia-Pacific: Distribution by Therapeutic Area, 2023-2035
    - 13.9.3.1.1. Super Generics Market for Oncological Disorders in Asia-Pacific, 2023-2035
    - 13.9.3.1.2. Super Generics Market for Metabolic Disorders in Asia-Pacific, 2023-2035
    - 13.9.3.1.3. Super Generics Market for Neurological Disorders in Asia-Pacific, 2023-2035
    - 13.9.3.1.4. Super Generics Market for Respiratory Disorders in Asia-Pacific, 2023-2035
    - 13.9.3.1.5. Super Generics Market for Cardiovascular Disorders in Asia-Pacific, 2023-2035
    - 13.9.3.1.6. Super Generics Market for Other Disorders in Asia-Pacific, 2023-2035
  - 13.9.3.2. Super Generics Market Distribution by Route of Administration in Asia-Pacific
    - 13.9.3.2.1. Super Generics Market for Oral Route of Administration in Asia-Pacific, 2023-2035
    - 13.9.3.2.2. Super Generics Market for Subcutaneous Route of Administration in Asia-Pacific, 2023-2035
    - 13.9.3.2.3. Super Generics Market for Intravenous Route of Administration in Asia-Pacific, 2023-2035
    - 13.9.4.2.4. Super Generics Market for Other Routes of Administration in Asia-Pacific, 2023-2035
  - 13.9.3.3. Super Generics Market: Distribution by Type of Molecule in Asia-Pacific
    - 13.9.3.3.1. Super Generics Market for Small Molecule in Asia-Pacific, 2023-2035
    - 13.9.3.3.2. Super Generics Market for Biologics in Asia-Pacific, 2023-2035
  - 13.9.3.4. Super Generics Market: Distribution by Type of Small Molecules in Asia-Pacific
    - 13.9.3.4.1 Super Generics Market for Complex Generics in Asia-Pacific, 2023-2035
    - 13.9.3.4.2. Super Generics Market for Other Small Molecules in Asia-Pacific, 2023-2035
  - 13.9.3.5. Super Generics Market: Distribution by Type of Product Offered in Asia-Pacific
    - 13.9.3.5.1. Super Generics Market for Prefilled Syringe in Asia-Pacific, 2023-2035
    - 13.9.3.5.2. Super Generics Market for Vials in Asia-Pacific, 2023-2035
    - 13.9.3.5.3. Super Generics Market for Aerosols in Asia-Pacific, 2023-2035
    - 13.9.3.5.4. Super Generics Market for Tablets in Asia-Pacific, 2023-2035
    - 13.9.3.5.5. Super Generics Market for Capsules in Asia-Pacific, 2023-2035
    - 13.9.3.5.6. Super Generics Market for Other Types of Products in Asia-Pacific, 2023-2035
- 13.9.4. Super Generics Market in Rest of the World, 2023-2035
  - 13.9.4.1. Super Generics Market in Rest of the World: Distribution by Therapeutic Area, 2023-2035
    - 13.9.4.1.1. Super Generics Market for Oncological Disorders in Rest of the World, 2023-2035
    - 13.9.4.1.2. Super Generics Market for Metabolic Disorders in Rest of the World, 2023-2035
    - 13.9.4.1.3. Super Generics Market for Neurological Disorders in Rest of the World, 2023-2035
    - 13.9.4.1.4. Super Generics Market for Respiratory Disorders in Rest of the World, 2023-2035
    - 13.9.4.1.5. Super Generics Market for Cardiovascular Disorders in Rest of the World, 2023-2035
    - 13.9.4.1.6. Super Generics Market for Other Disorders in Rest of the World, 2023-2035
  - 13.9.4.2. Super Generics Market Distribution by Route of Administration in Rest of the World
    - 13.9.4.2.1. Super Generics Market for Oral Route of Administration in Rest of the World, 2023-2035
    - 13.9.4.2.2. Super Generics Market for Subcutaneous Route of Administration in Rest of the World, 2023-2035
    - 13.9.4.2.3. Super Generics Market for Intravenous Route of Administration in Rest of the World, 2023-2035
    - 13.9.4.2.4. Super Generics Market for Other Routes of Administration in Rest of the World, 2023-2035
  - 13.9.4.3. Super Generics Market: Distribution by Type of Molecule in Rest of the World
    - 13.9.4.3.1. Super Generics Market for Small Molecule in Rest of the World, 2023-2035
    - 13.9.4.3.2. Super Generics Market for Biologics in Rest of the World, 2023-2035
  - 13.9.4.4. Super Generics Market: Distribution by Type of Small Molecules in Rest of the World
    - 13.9.4.4.1 Super Generics Market for Complex Generics in Rest of the World, 2023-2035
    - 13.9.4.4.2. Super Generics Market for Other Small Molecules in Rest of the World, 2023-2035
  - 13.9.4.5. Super Generics Market: Distribution by Type of Product Offered in Rest of the World
    - 13.9.4.5.1. Super Generics Market for Prefilled Syringe in Rest of the World, 2023-2035
    - 13.9.4.5.2. Super Generics Market for Vials in Rest of the World, 2023-2035
    - 13.9.4.5.3. Super Generics Market for Aerosols in Rest of the World, 2023-2035
    - 13.9.4.5.4. Super Generics Market for Tablets in Rest of the World, 2023-2035
    - 13.9.4.5.5. Super Generics Market for Capsules in Rest of the World, 2023-2035
    - 13.9.4.5.6. Super Generics Market for Other Types of Products in Rest of the World, 2023-2035

한글목차

목차

제1장 서문

제2장 조사 방법

제3장 경제 및 기타 프로젝트 특유의 고려사항

제4장 주요 요약

제5장 서론

제6장 슈퍼 제네릭 의약품 : 시장 구도

제7장 슈퍼 제네릭 기술 : 시장 구도

제8장 기술 경쟁 분석

제9장 기업 개요

제10장 사례 연구 : 승인을 획득한 슈퍼 제네릭 의약품

제11장 슈퍼 제네릭 의약품 : 유망한 의약품 후보

제12장 SWOT 분석

제13장 세계의 슈퍼 제네릭 의약품 시장